SEC Form 4 · accession 0001593968-18-000496
Avinger Inc · AVGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Himanshu Patel
Officer — CTO
Period of report
Feb 16, 2018
Accepted (ET)
Mar 5, 2018 · 8:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001506928
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2018 | J | 62 | $0.9265 | A | 2,484 | D | |
| Series B Preferred StockF2 | Feb 16, 2018 | P | 50 | $1,000.00 | A | 50 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series 1 Warrants | $2.00 | Feb 16, 2018 | P | 25,000 | A | Feb 16, 2018 | Feb 17, 2025 | Common Stock | 25,000 | 31,725 | D |
| Series 2 WarrantsF3 | $2.00 | Feb 16, 2018 | P | 25,000 | A | Feb 16, 2018 | Feb 17, 2025 | Common Stock | 25,000 | 56,725 | D |
Explanation of responses
- F1The reporting person is a participant of the 2015 Employee Stock Purchase Plan, which made a purchase for $0.9265 per share consideration of Common Stock of the Issuer on March 1, 2018.
- F2These shares were purchased by the reporting person in connection with an underwritten public offering by the Issuer. The offering closed on February 16, 2018. The reported sale price reflects the price at which the reporting person purchased the shares from the underwriters.
- F3The Series 2 Warrants expire the earlier of (i) 5:00 pm New York City time on February 17, 2025 and (ii) sixty days following the announcement of FDA clearance to market Pantheris, provided, however, if at any time during such 60-day period the VWAP for any trading day is less than the exercise price, the termination date shall be extended to February 17, 2025.